Company overview

Penumbra, Inc., headquartered in Alameda, California, is a global healthcare company focused on innovative therapies. Penumbra designs, develops, manufactures and markets novel products and has a broad portfolio that addresses challenging medical conditions in markets with significant unmet need. Penumbra sells its products to hospitals and healthcare providers primarily through its direct sales organization in the United States, most of Europe, Canada and Australia, and through distributors in select international markets. The Penumbra logo is a trademark of Penumbra, Inc. Members of the Penumbra team agree that this is where their work has meaning -- we are transforming the treatment of some of the world's most devastating conditions. Penumbra is where everyone's ideas matter, and where learning and growth are constant.No. 5 on the Greater Bay Area Manufacturers List, San Francisco Business Times, 2020100 Fastest-Growing Companies, Fortune, 2019Review our community guidelines for LinkedIn here: https://bit.ly/2Jmbw83.
Founded in 2004
Alameda, California, USA
2.9K employees (140 in marketing)
53% recommend to a friend
52% positive business outlook

Salaries

Typical salary range

$115,000 – $145,000

/ yr

Help build salary transparency at Penumbra, Inc.

Share your compensation anonymously to see full data.

Contribute

People

Hiring activity

Open marketing jobs over time

5 open now

Headcount trend

Company growth over the last 12 months

Headcount +10.5% year over year

Funding

Total funding

$2.9M

Last raise

$2.7M

Post IPO Equity, 5 years ago

Funding history

Aug 2021

Post IPO Equity Penumbra · $2.7M

Nov 2012

Seed Round Penumbra · $121.2K

Audience

Monthly website visitors
46.4K
Month over month-4%
Quarter over quarter+2.9%
Top sourceSearch (54.2%)
Ad budget per month$0.0
Average search rank52.7
Traffic source mix
Search
54.2%
Direct
37.9%
Referral
5.6%
Social
1.2%
Paid referral
0.9%

LinkedIn followers

Follower count and growth

Total followers

76.2K

12-mo growth

+32.6%

Monthly growth

+3.7%

News

Links